Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Some people with hard-to-treat mantle cell lymphoma survived over 5 years with CAR-T therapy, offering durable hope for this aggressive cancer.
This 5-year follow-up of the pivotal ZUMA-2 trial (N=68) confirms durable responses with brexucabtagene autoleucel CAR-T therapy in relapsed/refractory mantle cell lymphoma, with median OS of 46.5 months and median DOR of 36.5 months. Complete responders showed median OS of 60.2 months, supporting long-term benefit and continued clinical use of brexu-cel in R/R MCL.
What the study was
- Study design
- Clinical trial follow-up (pivotal cohort extension)
- Population
- Adults with relapsed/refractory mantle cell lymphoma (R/R MCL) after ≥2 prior therapies
- Sample size
- 68
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Hematology & Oncology
Why it surfaced
5-year long-term follow-up data for the only approved CAR-T in MCL; confirms durable survival benefit with established safety profile in high-unmet-need R/R MCL population. Pivotal trial cohort, n=68, median follow-up 67.8 months.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.